Good news! After review by the National Medical Products Administration (NMPA), Jiudian Pharmaceutical’s Nicorandil Tablets have been approved for market, and have simultaneously passed the consistency evaluation of generic drug quality and efficacy. As a dual-listed product in both the National Essential Drug List and the Class A Reimbursable Drug List, this medication offers patients a new option with superior efficacy and safety, thanks to its unique dual-action mechanism and significant clinical benefits.

Nicorandil Tablets are a first-line treatment for coronary microvascular angina, long-term medication for chronic stable angina, and an alternative for patients intolerant to nitrates. They are used to treat unstable angina and other acute coronary syndrome conditions, and has been included in several authoritative treatment guidelines, including the Guideline for Rational Use of Coronary Heart Disease (2nd Edition), Diagnosis and Treatment Guidelines for Non-ST-Elevation Acute Coronary Syndrome, and Guideline for Rational Use of Drugs in ST-Elevation Myocardial Infarction in Primary Care. Clinical studies have shown that Nicorandil significantly reduces the all-cause mortality rate by 35% in angina patients, and reduces the risk of cardiovascular events such as coronary heart disease-related deaths and non-fatal myocardial infarction by 17%. Additionally, the drug has a wide range of indications, including exertional, variant, unstable angina, and post-myocardial infarction angina, with no significant impact on blood pressure or heart rate, further improving its safety profile.

Nicorandil Tablets first entered the Chinese market in 2006, and with the increasing number of coronary heart disease patients and growing nitrate drug tolerance issues, the clinical demand for Nicorandil has continued to rise. According to third-party statistics, in 2023, the sales of Nicorandil in public hospitals and primary healthcare facilities reached 771 million yuan. In the first half of 2024, sales grew by 14.4% year-on-year, reaching 441 million yuan.

The approval of Nicorandil Tablets by Jiudian Pharmaceutical complements the company’s existing cardiovascular product line, creating synergistic effects. With its dual-action mechanism, guideline recommendations, and inclusion in medical insurance coverage, Nicorandil Tablets are expected to become a core drug in the treatment of angina and benefit more patients.